SANA - Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting | Benzinga
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.
| Details of the poster presentations are as follows: |
| Title: |
| Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell Therapy |
| Abstract Number: |
| 3437 |
| Session Name: |
| 703. Cellular Immunotherapies: Basic and Translational: Poster II |
| Session Date: |
| Sunday, December 10, 2023 |
| Presentation Time: |
| 6:00 PM - 8:00 PM |
| Location: |
| San Diego Convention Center, Halls G-H |
| Title: |
| Efficient and Specific In Vivo Genetic Engineering of Human Hematopoietic Stem Progenitor Cells without Selective Conditioning |
| Abstract Number: |
| 2252 |
| Session Name: |
| 801. Gene Therapies: Poster I |
| Session Date: |
| Saturday, December 9, 2023 |
| Presentation Time: |
| 5:30 PM - 7:30 PM |
| Location: |
| San Diego Convention Center, Halls G-H |
| Title: |
| Development of a Novel, Allogeneic ... |